3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Terminated
2
Sponsor Class
OTHER
5
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Conditions
Carcinoma, Non-Small-Cell Lung
114
Neoplasms
28
Lung Neoplasms
24
Non-Squamous Non-Small Cell Lung Cancer
21
Pancreatic Neoplasms
13
Colorectal Neoplasms
6
Neoplasm Metastasis
5
Breast Neoplasms
4
Respiratory Tract Neoplasms
3
Respiratory Tract Diseases
3
Lymphoma
3
Thoracic Neoplasms
2
Solid Tumors
2
Recurrence
2
Neoplasms by Site
2
Lung Diseases
2
Familial ependymoma
2
Ependymoma
2
Carcinoma, Renal Cell
2
Carcinoma, Hepatocellular
2
Carcinoma
2
Bronchial Neoplasms
2
Advanced Solid Tumors
2
Vascular Diseases
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumor
1
Smoking
1
Small Cell Lung Carcinoma
1
Interventions
Carboplatin
30
Cisplatin
23
pembrolizumab
22
Paclitaxel
21
Pemetrexed
20
Gemcitabine
10
osimertinib
9
durvalumab
9
Nivolumab
9
130-nm albumin-bound paclitaxel
8
Sunitinib
7
Sorafenib
7
Fluorouracil
7
Everolimus
7
Docetaxel
7
Axitinib
7
Cetuximab
6
epothilone B
5
1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine
5
volociximab
4
trebananib
4
reolysin
4
catumaxomab
4
cabozantinib
4
atezolizumab
4
Radiotherapy
4
Ipilimumab
4
vosaroxin
3
liposomal doxorubicin
3
lenvatinib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Carcinoma
×
Erlotinib Hydrochloride
×
Clear all
NCT02134015
2018-01-23
HER3-Lung
Daiichi Sankyo
Phase 3
Terminated
145 enrolled
20 charts
NCT00673049
2013-07-24
NSCLC
Pfizer
Phase 3
Terminated
583 enrolled
11 charts